Radiation therapy is often thought of as a treatment that only has a role in early-stage disease. This is no longer the case, and this approach to treatment can be used in several different ways even ...
For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower ...
What is stereotactic radiation therapy for prostate cancer? How does it compare to other treatments?
Prostate cancer is Australia's most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start ...
India, June 17 -- Thousands of men with prostate cancer will be provided with high-powered 'precision' radiation on the NHS, ...
Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...
We investigated whether prostate cancer patients treated with external beam radiation therapy (EBRT) have a higher cumulative incidence of secondary cancer compared with patients treated with radical ...
An interview with Dr. Scott Morgan from the Ottawa Hospital and University of Ottawa on "Hypofractionated Radiation Therapy for Localized Prostate Cancer: an ASTRO, ASCO, and AUA Evidence-Based ...
Reviewed by Peter E. Lonergan, MD, FRCS (Urol.), consultant urologist and clinical senior lecturer at St. James’s Hospital & Trinity College in Dublin, Ireland. If you have prostate cancer and ...
Months after exiting its listed Indian subsidiary, Novartis has reinforced its commitment to the country's innovative ...
About 4,500 men are diagnosed with prostate cancer in New Zealand every year, and more than 700 will die from it.
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results